A clinical study published in Scientific Reports indicates that Bridge Capture can identify significant mutations in blood samples from patients with metastatic colorectal cancer.

TURKU, Finland, July 14, 2025 — Genomill Health, a biotechnology firm specializing in streamlined targeted library preparation for next-generation sequencing (NGS), has released the findings of a clinical pilot study. Published in Scientific Reports, these results highlight the exceptional sensitivity of its Bridge Capture technology for profiling mutations in cell-free DNA from metastatic colorectal cancer patients. The study demonstrates that Bridge Capture achieves sensitivity comparable to droplet digital PCR (ddPCR), which is considered a gold standard, while also offering limitless panel scalability and a straightforward, economical workflow that supports decentralized NGS testing.

The study, conducted in collaboration with Professor Ari Ristimäki’s group at Helsinki University Hospital, demonstrated strong agreement between Bridge Capture and both ddPCR and Ion AmpliSeq. It also uncovered several previously unidentified oncogenic mutations, which correlated with disease progression in longitudinal plasma samples. Prof. Ristimäki expressed admiration for Bridge Capture’s ability to merge highly scalable, sensitive targeted sequencing with cost-effectiveness and user-friendliness. He considers this a significant advancement that could vastly expand the application of liquid biopsies in monitoring treatment.

“Bridge Capture performed as well as, or better than, established gold-standard methods for detecting mutations in patient samples. Its capacity to track changes over time could prove to be an invaluable asset for monitoring cancer progression and relapse,” stated Simona Adamusová, Doctoral Researcher and co-first author.

Manu Tamminen, CEO and Co-Founder of Genomill, further remarked, “This clinical pilot study underscores Bridge Capture’s readiness for practical implementation in liquid biopsy. The unmatched simplicity of its lab workflow and its compatibility with various sequencing platforms pave the way for distributed, decentralized, longitudinal cancer diagnostics. By eliminating the cost and infrastructure barriers currently impeding the routine use of liquid biopsies, we aim to establish Bridge Capture as a foundational technology for widely accessible cancer diagnostics.”

Bridge Capture exemplifies Genomill’s Geno1^® technologies, which are founded on circular DNA and linear DNA amplification. Juha-Pekka Pursiheimo, CTO and inventor of the technology, commented, “Bridge Capture sets a new benchmark for NGS library design by utilizing circular single-stranded DNA – an option that is more adaptable and robust than conventional linear libraries. Coupled with our PCR-free DNA amplification methods, this innovation positions Genomill to transform NGS library preparation.”

The complete study, titled “Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients”, is accessible in Scientific Reports (link ).

For additional details regarding Genomill, please visit .

Logo –

Contact Information

CEO Manu Tamminen

Phone: +358403513712

SOURCE: Genomill Health